Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: A multicenter retrospective study

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2545-2550

  Hosokawa, Ayumu ^a   Ogawa, Kohei ^a   Ando, Takayuki ^a   Suzuki, Nobuhiro ^a   Ueda, Akira ^a   Kajiura, Shinya ^a   Kobayashi, Yuka ^b   Tsukioka, Yuji ^c   Horikawa, Naoki ^c   Yabushita, Kazuhisa ^c   Fukuoka, Junya ^a   Sugiyama, Toshiro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Tachikawa General Hospital   (Japan)

^c Takaoka City Hospital   (Japan)

Author keywords

Colorectal cancer; FOLFOX; Goshajinkigan; Neurotoxicity; Shakuyakukanzoto; Traditional Japanese medicine

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; GOSHAJINKIGAN; HERBACEOUS AGENT; OXALIPLATIN; SHAKUYAKUKANZOTO; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; HYPERSENSITIVITY; HYPOKALEMIA; LEUKOPENIA; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TRADITIONAL MEDICINE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUGS, CHINESE HERBAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES;

EID: 84865701882     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
2. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
3. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Chitaley U, Alberts SR and Loprinzi CL: Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 29: 421-427, 2011.
4. Ishibashi K, Okada N, Miyazaki T, Sano M and Ishida H: Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol 15: 82-87, 2010.
5. von Delius S, Eckel F, Wagenpfeil S, Mayr M, Stock K, Kullmann F, Obermeier F, Erdmann J, Schmelz R, Quasthoff S, Adelsberger H, Bredenkamp R, Schmid RM and Lersch C: Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 25: 173-180, 2007.
6. Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, Gourzis P, Assimakopoulos K and Kalofonos HP: Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 67: 2253-2255, 2006.
7. Tawata M, Kurihara A, Nitta K, Iwase E, Gan N and Onaya T: The effects of goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy. Diabetes Res Clin Pract 26: 121-128, 1994.
8. Kono T, Mamiya N, Chisato N, Ebisawa Y, Yamazaki H, Watari J, Yamamoto Y, Suzuki S, Asama T and Kamiya K: Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Complement Alternat Med, in press.
9. Nishioka M, Shimada M, Kurita N, Iwata T, Morimoto S, Yoshikawa K, Higashijima J, Miyatani T and Kono T: The Kampo medicine, goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol 16: 322-327, 2011.
10. Yamamoto K, Hoshiai H and Noda K: Effects of shakuyaku-kanzo-to on muscle pain from combination chemotherapy with paclitaxel and carboplatin. Gynecol Oncol 81: 333-334, 2001.
11. Hyodo T, Taira T, Takemura T, Yamamoto S, Tsuchida M, Yoshida K, Uchida T, Sakai T, Hidai H and Baba S: Immediate effect of shakuyaku-kanzo-to on muscle cramp in hemodialysis patients. Nephron Clin Pract 104: c28-32, 2006.
12. Hinoshita F, Ogura Y, Suzuki Y, Hara S, Yamada A, Tanaka N, Yamashita A and Marumo F: Effect of orally administered shao-yao-gan-cao-tang (shakuyaku-kanzo-to) on muscle cramps in maintenance hemodialysis patients: a preliminary study. Am J Chin Med 31: 445-453, 2003.
13. Fujii K, Okamoto S, Saitoh K, Sasaki N, Takano M, Tanaka S, Kudoh K, Kita T, Tode T and Kikuchi Y: The efficacy of shakuyaku-kanzo-to for peripheral nerve dysfunction in paclitaxel combination chemotherapy for epithelial ovarian carcinoma. Gan To Kagaku Ryoho 31: 1537-1540, 2004 (in Japanese).
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
15. Boku N, Ohtsu A, Hyodo I, Shirao K, Miyata Y, Nakagawa K, Tamura T, Hatake K and Tanigawara Y: Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. Jpn J Clin Oncol 37: 440-445, 2007.
16. Suzuki Y, Goto K, Ishige A, Komatsu Y and Kamei J: Antinociceptive mechanism of gosha-jinki-gan in streptozotocin-induced diabetic animals: role of nitric oxide in the periphery. Jpn J Pharmacol 79: 387-391, 1999.
17. Omiya Y, Suzuki Y, Yuzurihara M, Murata M, Aburada M, Kase Y and Takeda S: Antinociceptive effect of shakuyakukanzoto, a Kampo medicine, in diabetic mice. J Pharmacol Sci 99: 373-380, 2005.
18. Gamelin L, Boisdron-Celle M, Delva R, Guérin-Meyer V, Ifrah N, Morel A and Gamelin E: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10: 4055-4061, 2004.
19. Homma M, Ishihara M, Qian W and Kohda Y: Effects of long term administration of shakuyaku-kanzo-to and shosaiko-to on serum potassium levels. Yakugaku Zasshi 126: 973-978, 2006 (in Japanese).
20. Kinoshita H, Okabayashi M, Kaneko M, Yasuda M, Abe K, Machida A, Ohkubo T, Kamata T and Yakushiji F: Shakuyaku-kanzo-to induces pseudoaldosteronism characterized by hypokalemia, rhabdomyolysis, metabolic alkalosis with respiratory compensation, and increased urinary cortisol levels. J Altern Complement Med 15: 439-443, 2009.